$GILD Company News 10 stocks loved by advisers who beat

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2014 at 12:28 PM

$GILD Company News

10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Gilead’s new drug is even pricier than Sovaldi 5:29 p.m. Oct. 10, 2014 - Russ Britt
The most profitable companies get the best stock returns 8:31 a.m. Oct. 10, 2014 - Philip van Doorn
Bristol-Myers drops Hepatitis C dual regimen in U.S. 11:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
Mylan boosts full-year outlook on product launches 8:11 a.m. Oct. 3, 2014 - MarketWatch.com
During times like these, cash is king 2:03 p.m. Oct. 2, 2014 - The Trading Deck
Sovaldi pricing raises debate over drug costs 2:57 p.m. Oct. 1, 2014 - Jani Actman of Medill News Service
It’s crucial to watch growth stocks right now 3:06 p.m. Sept. 25, 2014 - The Trading Deck
Gilead Sciences shares up 1.5% 9:39 a.m. Sept. 25, 2014 - Sue Chang
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Market pullbacks present promise, not peril 1:58 p.m. Sept. 16, 2014 - The Trading Deck
Gilead Sciences shares slide 2.6% 9:39 a.m. Sept. 15, 2014 - Sue Chang
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results 35 min ago - TheStreet.com
Regulus up big premarket on HCV therapeutic results 9:21 a.m. Today - Seeking Alpha
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results 8:39 a.m. Today - TheStreet.com
Priceline Is On Sale 6:54 a.m. Today - Seeking Alpha
Biogen Leads 5 Top Biotech Stocks As Earnings Loom 6:56 p.m. Oct. 21, 2014 - Investors Business Daily
Gilead Sciences: Pricing, Politics And Profits 3:23 p.m. Oct. 21, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – AMGN GILD REGN ACHN 2:00 p.m. Oct. 21, 2014 - InvestorPlace.com
BI begins enrollment in Phase 3 CRC trial 9:08 a.m. Oct. 21, 2014 - Seeking Alpha
Gilead Sciences: Clear The Dockets And Settle With Merck Already 9:07 a.m. Oct. 21, 2014 - Seeking Alpha
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
3 Drugs Stocks Pushing Industry Growth 1:17 p.m. Oct. 20, 2014 - TheStreet.com
Stocks Slide on Indiscriminate Selling 10:40 a.m. Oct. 20, 2014 - Barrons.com
LabCorp launches new HIV test 10:40 a.m. Oct. 20, 2014 - Seeking Alpha
Gilead: Stage Set For Rally 8:27 a.m. Oct. 20, 2014 - Seeking Alpha
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies 7:40 a.m. Oct. 20, 2014 - Seeking Alpha
Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14) 6:24 a.m. Oct. 19, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors 6:00 a.m. Oct. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:16 p.m. Oct. 17, 2014 - TheStreet.com
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog 4:30 p.m. Oct. 17, 2014 - Zacks.com
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now 1:54 p.m. Oct. 17, 2014 - Seeking Alpha

Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 5:00 p.m. Oct. 21, 2014 - BusinessWire - BZX
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 6:23 a.m. Sept. 19, 2014 - BusinessWire - BZX
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer 6:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’ 6:21 p.m. Sept. 16, 2014 - BusinessWire - BZX
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C 5:50 p.m. Sept. 16, 2014 - Marketwire
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries 6:30 a.m. Sept. 15, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beauty Industry's $56B Boom: Trends and Innovations

A Whopping $56 Billion Beauty Surge U.S. beauty sales have jumped by 7%, translating into a dizzying $56 billion 'feel-good effect' in the industry. People are shelling out for products that make them look and feel their best. This isn't just about vanity—consumers are investing in self-care and wellness, a trend shaping what we see on the vanity counter. Every spritz...

Dahua Dives Deep into AIoT at IFA Berlin 2026

Dahua's AIoT Vision Unfolds in Berlin Forget the coffee runs and the all-too-dry boardroom discussions—Dahua Technology has taken the stage at IFA Berlin 2026 and they're not just singing the same old tune. They're blasting through innovation barriers with a mix of AIoT—the next-gen tech cocktail everyone’s buzzing about. Leveraging AIoT might sound like...

BMO Sheds U.S. Branches, Eyes Strategic Growth

Why BMO is Slimming Down in the States You know, when a heavyweight like BMO Financial Group starts shedding branches left and right, you gotta ask yourself what the grand plan is. In a move that looks more like a strategic dance than an abrupt U-turn, BMO's gotten rid of 138 U.S. branches, handing them over to First-Citizens Bank. We're talking outlets scattered from...

Postal Service Defends New Rule Amid Speculation

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Carestream's Enhanced DRX-LC: Imaging Game Changer

Rethinking Long-Length Imaging with Carestream The medical imaging sector just got a shot in the arm with Carestream Healthcare International's latest leap in technology. The DRX?LC Detector is not just a fancy update — it's a full-on revolution for long?length imaging. Forget the old days of piecing multiple exposures together, because this innovation simplifies...

Agroz: Awards Fuel Momentum in AgriTech Sphere

Agroz Surging Ahead with Global Acclaim There's a new breeze blowing through the AgTech industry, and it's carrying Agroz Inc. (NASDAQ: AGRZ) straight to the top. Fresh off the back of snagging several prestigious international awards, this vertically integrated agricultural tech powerhouse is making waves not just in Malaysia, but on the global stage. Top of the FoodTech...

Pathlock Faces Identity Governance Opportunities in 2026

Challenges in Identity Governance Emerge for 2026 Imagine a world where digital identities run wild—unmonitored, orphaned, dormant. Welcome to 2026, where identity governance and administration (IGA) face a reckoning, dragging enterprises into the spotlight as they scramble to protect against identity chaos. With Pathlock’s recent recognition in the Gartner Market...

Restaurant Industry Bolsters Safety with New Guide

There’s a fresh playbook hitting the shelves, and it’s aimed at the heart of the dining world—a guide that tackles the nasty curveballs of public safety incidents. Restaurants, the places we count on for warm meals and cold drinks, aren’t just about what’s on the menu; they're about keeping folks safe, too. The National Restaurant Association just dropped a new...

Orbis Celebrates 20 Years of Eye Care in Macau

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

DELIVAN Unveils Electric Vans and Expansion in Europe

DELIVAN Charging Forward with All-Electric Vans Mark the calendar—September 4, 2026, marked a big day for DELIVAN. The company's foray into the European market is getting serious, splashed across IAA Transportation in all its glory. Unveiling two fresh all-electric production vans, DELIVAN's not just tiptoeing onto the scene; it's diving headfirst into Europe's buzzing...